Salubris Bio's JK06 shows promising results in early overseas trials for solid tumors

Salubris Bio, a subsidiary of Shenzhen Salubris Pharmaceuticals, announced preliminary data from the I/II phase clinical trial of JK06. The results were presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting.

The trial assessed JK06 in 34 patients with advanced recurrent/refractory solid tumors who had failed prior standard treatments. Of the 29 evaluable patients, 6 achieved confirmed partial response (PR), resulting in an objective response rate (ORR) of 21%.

Notably, among 13 non-small cell lung cancer (NSCLC) patients, 5 achieved confirmed PR, with an ORR of 38% and the longest response lasting 30 weeks. In 7 breast cancer patients, 1 achieved confirmed PR, maintaining a response for 18 weeks. Partial responses were observed across several dose groups.

JK06, a selective 5T4-targeted bispecific antibody-drug conjugate (ADC), demonstrated good overall tolerability. Most treatment-related adverse events were Grade 1 or 2. The company emphasized this data represents only partial progress and that successful drug registration and launch are subject to further clinical development and regulatory approvals.